Definitive Contract HHSN272201700077C
Award Date
9/1/17
Potential Completion Date
7/21/20
Potential Value
$3.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Profectus Biosciences, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Baltimore, MD 21224, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Profectus Biosciences, Inc., a small business concern, for the development of novel vaccine technologies and strategies. The contract has a total potential value of $322,336.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Profectus Biosciences, Inc., a small business. The contract, valued at $4,214,664.98, is for the production of a pDNA vaccine expressing FLSC as part of the agency's Staged Vaccine Development program. The contract does not have a set-aside designation. The contract supports the development of novel vaccine...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $20,654,816.99, cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to United Biomedical, Inc. for HIV vaccine design and development teams for prevention and treatment. The contract has a completion date of June 29, 2010 and was awarded on June 30, 2005. This contract is not associated with a set-aside and does not indicate the use of any small business program. United Biomedical, Inc. is a for-profit, self-certified...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to International AIDS Vaccine Initiative Inc. (IAVI), a non-profit organization. The $713,906.00 award supports the development of nanoparticle-based delivery systems for human immunodeficiency virus type 1 (HIV-1) biomolecules. The contract has a performance period ending on December 15, 2021 and utilizes a Cost...
This is a $600,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services (HHS), to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to develop an effective human immunodeficiency virus (HIV) vaccine using engineered nanoparticles loaded with messenger RNA (mRNA) targeted to antigen presenting cells. This contract is part of the Small Business Innovation Research (SBIR)...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases, under NIAID's Broad Agency Announcement (BAA) Research Area 001. AAHI...